0001209191-14-023258.txt : 20140326
0001209191-14-023258.hdr.sgml : 20140326
20140326175943
ACCESSION NUMBER: 0001209191-14-023258
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20140326
FILED AS OF DATE: 20140326
DATE AS OF CHANGE: 20140326
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: APPLIED GENETIC TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0001273636
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 593553710
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 11801 RESEARCH DRIVE
STREET 2: SUITE D
CITY: ALACHUA
STATE: FL
ZIP: 32615
BUSINESS PHONE: 386-462-2204
MAIL ADDRESS:
STREET 1: 11801 RESEARCH DRIVE
STREET 2: SUITE D
CITY: ALACHUA
STATE: FL
ZIP: 32615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MedImmune Ventures, Inc.
CENTRAL INDEX KEY: 0001291884
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36370
FILM NUMBER: 14719687
BUSINESS ADDRESS:
STREET 1: ONE MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 301-398-0000
MAIL ADDRESS:
STREET 1: ONE MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2014-03-26
0
0001273636
APPLIED GENETIC TECHNOLOGIES CORP
AGTC
0001291884
MedImmune Ventures, Inc.
ONE MEDIMMUNE WAY
GAITHERSBURG
MD
20878
0
0
1
0
Series A-1A Convertible Preferred Stock
Common Stock
690678
D
Series B-1 Convertible Preferred Stock
Common Stock
183126
D
Series B-2 Convertible Preferred Stock
Common Stock
339826
D
Series B-3 Convertible Preferred Stock
Common Stock
162831
D
Series B-1 Warrant (Right to Buy)
0.1297
2017-05-02
Series B-1 Preferred Stock
416361
D
Each share of Series A-1 convertible preferred stock is convertible into shares of common stock at any time at the holder's election or upon consummation of a qualified public offering of the registrant on an approximately 1-for-16.62 basis. The Series A-1 convertible preferred stock has no expiration date.
Each share of Series B-1, B-2 and B3 convertible preferred stock is convertible into shares of common stock at any time at the holder's election or upon the consummation of a qualified public offering of the registrant on a 1-for-35 basis. The Series B-1, B-2 and B-3 convertible preferred stock has no expiration date.
The Series B-1 Warrant is exercisable for shares of Series B-1 convertible preferred stock at any time until the expiration of the warrant at the holder's election.
/s/ Hemmie Chang, attorney-in-fact for MedImmune Ventures, Inc.
2014-03-26
EX-24.3_515862
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby authorizes Erica Rice,
Hemmie Chang and Robert W. Sweet, Jr., each of Foley Hoag LLP, to execute for
and on behalf of the undersigned, in the undersigned's capacity as a stockholder
of Applied Genetic Technologies Corporation (the "Company"), a Form ID, Forms 3,
4 and 5, and any amendments thereto, and cause such form(s) to be filed with the
United States Securities and Exchange Commission pursuant to Section 16(a) of
the Securities Act of 1934, relating to the undersigned's beneficial ownership
of securities in the Company. The undersigned hereby grants to the
attorney-in-fact full power and authority to do and perform any and every act
and thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do personally present, with full
power of substitution, resubstitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney's-in-fact substitute
or substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorney-in-fact, in serving in such capacity at the request
of the undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 26th day of March, 2014.
MedImmune Ventures, Inc.
/s/ David E. White
David E. White, Treasurer